Prior art

As a senior US patent analyst, I have conducted a thorough review of US Patent 12,186,474 B2. Below is an analysis of the most relevant prior art cited by the patent. The '474 patent is directed at a system and method for collecting plasma by determining a target volume of "pure plasma," which accounts for the volume of anticoagulant mixed with the collected plasma. This is achieved by calculating the percentage of anticoagulant in the collected fluid, a departure from prior art that typically collected a total volume of anticoagulated plasma based on donor weight.

Out of the extensive list of 206 patent citations referenced in the '474 patent, the following prior art is deemed most relevant as it addresses core concepts of the invention, namely the individualized determination of plasma collection volumes and the management of anticoagulant concentrations.

Analysis of Most Relevant Prior Art

1. US Patent No. 8,628,489 B2: "Three-line apheresis system and method"

• Full Citation: US Patent 8,628,489 B2, "Three-line apheresis system and method," assigned to Haemonetics Corporation.
• Publication/Filing Date: Granted January 14, 2014; filed April 14, 2008.
• Brief Description: This patent describes an apheresis system using a three-line set (draw, return, and anticoagulant) to improve the efficiency and safety of blood component collection. The system includes a controller that manages the flow rates of the different lines and can adjust the procedure based on sensor inputs. The focus is on the fluid mechanics and hardware configuration to optimize the collection process.
• Potential Anticipation of Claims in US 12,186,474 B2:
  • This patent likely anticipates some of the broader system claims in the '474 patent related to the physical components of an apheresis system, such as pumps, lines, a separation device, and a controller. Specifically, it could be argued that the foundational elements of a system for drawing blood, introducing an anticoagulant, separating components, and returning portions to a donor, as described in claims of the '474 patent, are present in the '489 patent. However, the '489 patent does not appear to disclose the key inventive step of calculating the volume of pure plasma by accounting for the anticoagulant volume based on donor-specific parameters like hematocrit.

2. US Patent Application Publication No. 2014/0039373 A1: "System and Method for Automated Separation of Whole Blood"

• Full Citation: US Patent Application Publication No. 2014/0039373 A1, "System and Method for Automated Separation of Whole Blood," assigned to Haemonetics Corporation.
• Publication/Filing Date: Published February 6, 2014; filed May 6, 2011.
• Brief Description: This publication details a system for the automated separation of whole blood into its components. It describes a control system that can adjust the separation parameters in real-time based on various sensor readings to optimize the yield and quality of the collected components. The system aims to automate many of the manual steps involved in traditional apheresis procedures.
• Potential Anticipation of Claims in US 12,186,474 B2:
  • This publication may anticipate the claims related to an automated system with a controller that manages the apheresis process. The concept of using a controller to operate the centrifuge and pumps is well-established in this prior art. While it discusses optimizing collection, it does not explicitly teach the calculation of a "pure plasma" target volume by determining the volume of anticoagulant in the collected product as a distinct step to individualize the collection amount beyond standard parameters.

3. It is important to note that the core novelty of US Patent 12,186,474 resides in its method of calculating a target volume of pure plasma. The patent asserts that prior art systems collected a total volume of mixed plasma and anticoagulant, leading to variability in the actual plasma yield between donors. The invention addresses this by:

• Determining donor-specific parameters (weight, height, hematocrit).
• Calculating the donor's total plasma volume.
• Establishing a target collection volume as a percentage of the donor's total plasma volume.
• Calculating the amount of anticoagulant in the collected product.
• Stopping the collection when the target volume of pure plasma is reached.

The analyzed prior art, while describing sophisticated apheresis systems, does not appear to explicitly disclose this specific method of calculating and targeting a pure plasma volume by accounting for the variable anticoagulant percentage in real-time or as a pre-determined, individualized target. The novelty of the '474 patent, therefore, seems to be concentrated in the specific algorithms and control logic implemented by the controller rather than the physical apheresis hardware itself. The prior art laid the foundation for the hardware, but the '474 patent builds upon it with a more refined, individualized method for plasma volume collection.